Surgical treatment of tumor-induced osteomalacia: A retrospective review of 40 cases with extremity tumors

BMC Musculoskeletal Disorders

Volumn 16, Issue 1, 2015, Pages

  Sun, Zhi Jian ^a   Jin, Jin ^a   Qiu, Gui Xing ^a   Gao, Peng ^a   Liu, Yong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Extremity; Surgical treatment; Tumor resection; Tumor induced osteomalacia

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; OCTREOTIDE TC 99M; PHOSPHORUS; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE ALLOGRAFT; BONE DENSITY; BONE METASTASIS; BONE TUMOR; CALCIUM URINE LEVEL; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEMOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; ONCOGENIC OSTEOMALACIA; ORTHOPEDIC SURGERY; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PREOPERATIVE CARE; RETROSPECTIVE STUDY; SOFT TISSUE TUMOR; SYMPTOM; TOTAL HIP PROSTHESIS; ARM; BONE NEOPLASMS; CHINA; COMPARATIVE STUDY; COMPLICATION; CURETTAGE; OSTEOMALACIA; OSTEOTOMY; REOPERATION; RISK FACTOR; SOFT TISSUE NEOPLASMS; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BONE NEOPLASMS; CHINA; CURETTAGE; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOMALACIA; OSTEOTOMY; REOPERATION; RETROSPECTIVE STUDIES; RISK FACTORS; SOFT TISSUE NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; UPPER EXTREMITY; YOUNG ADULT;

EID: 84924952158     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-015-0496-3     Document Type: Article

References (21)

1. Drezner MK. Tumor-induced osteomalacia. Rev Endocr Metab Disord. 2001;2:175-86.
2. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;18:R53-77.
3. Econs MJ, Drezner MK. Tumor-induced osteomalacia-unveiling a new hormone. N Engl J Med. 1994;330:1679-81.
4. Juppner H, Wolf M, Salusky IB. FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res. 2010;25:2091-7.
5. Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest. 2003;112:785-94.
6. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab. 2003;285:E1-9.
7. Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab. 2005;90:1012-20.
8. De Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res. 2002;17:1102-10.
9. Duet M, Kerkeni S, Sfar R, Bazille C, Liote F, Orcel P. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med. 2008;33:752-6.
10. Khadgawat R, Singh Y, Kansara S, Tandon N, Bal C, Seith A, et al. PET/CT localisation of a scapular haemangiopericytoma with tumour-induced osteomalacia. Singapore Med J. 2009;50:e55-7.
11. Andreopoulou P, Dumitrescu CE, Kelly MH, Brillante BA, Cutler PC, Wodajo FM, et al. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res. 2011;26:1295-302.
12. Ito N, Shimizu Y, Suzuki H, Saito T, Okamoto T, Hori M, et al. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. J Intern Med. 2010;268:390-4.
13. Jiang Y, Xia WB, Xing XP, Silva BC, Li M, Wang O, et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J Bone Miner Res. 2012;27:1967-75.
14. Khaliq W, Cheripalli P, Tangella K. Tumor-induced osteomalacia (TIO): atypical presentation. South Med J. 2011;104:348-50.
15. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1-30.
16. Harbeck B, Schocklmann H, Seekamp A, Czech N, Monig H. Tumor-induced osteomalacia: successful treatment by radio-guided tumor surgery. J Clin Rheumatol. 2009;15:31-4.
17. Hesse E, Rosenthal H, Bastian L. Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med. 2007;357:422-4.
18. Tutton S, Olson E, King D, Shaker JL. Successful Treatment of Tumor-Induced Osteomalacia with CT-Guided Percutaneous Ethanol and Cryoablation. J Clin Endocrinol Metab. 2012;97:3421-5.
19. Fuentealba C, Pinto D, Ballesteros F, Pacheco D, Boettiger O, Soto N, et al. Oncogenic hypophosphatemic osteomalacia associated with a nasal hemangiopericytoma. J Clin Rheumatol. 2003;9:373-9.
20. Uramoto N, Furukawa M, Yoshizaki T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx. 2009;36:104-5.
21. Sidell D, Lai C, Bhuta S, Barnes L, Chhetri DK. Malignant phosphaturic mesenchymal tumor of the larynx. Laryngoscope. 2011;121:1860-3.